Xeris Biopharma Holdings has officially filed its latest financial results with the SEC, providing investors with updated operational data and supporting exhibits for the current reporting period.
Xeris Biopharma filed an 8-K on 2026-11-05 carrying Item 2.02 (Results of Operations and Financial Condition), so quarterly results were released. The filing summary gives no revenue, earnings or guidance figures, so the direction cannot be judged from this text; actual numbers in the exhibit will set the move.
The filing states results of operations and financial condition were released under Item 2.02, with financial statements and exhibits under Item 9.01; specific figures are not given in the summary.
The 8-K was filed on 2026-11-05.
Xeris Biopharma Holdings, Inc. submitted an 8-K filing on November 5, 2026, detailing its latest results of operations and financial condition. The company included supplemental financial statements and exhibits as part of the regulatory disclosure.
The company reported its results of operations and financial condition, accompanied by relevant financial statements and exhibits.
The filing was submitted to the SEC on November 5, 2026.